Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2009, Vol. 29 Issue (01): 50-55    DOI:
    
Generation of High Affinity Monoclonal Antibody and Development of ciELISA Kit for Rapid Detection of Ractopamine
张海棠 ZHANG Hai-Tang zi-liang wang rui-guang deng gai-ping zhang guo-ying fan jin-qing jiang
Download: HTML   PDF(969KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Mixed anhydride(MA) was used to conjugate ractopamine (RAC) to bovine serum albumin(BSA) and obtained artificial antigen BSA-RAC identified by UV and SDS-PAGE. Balb/c mice were immunized with BSA-RAC and hybridoma lines that secrete RAC monoclonal antibody(mAb) were generated with cell fusion. A ciELISA kit for detection of RAC (RAC-Kit) was developed with RAC mAb and its traits were tested. The results indicated that BSA-RAC was synthesized successfully and its conjugation ratio of RAC to BSA was about 24.5∶1. Three hybridoma lines were filtered and the best one was 4D8, its affinity constant (Ka) was 1.65×1010L/mol. The detection limit of RAC-Kit was 0.5ng/ml and its detection range was 0.5 to 151ng/ml. The recoveries of RAC spiked in feed were 87.2% and in swine urine were 89.4%. The precision and accuracy of the assay as determined by inter-assay and intra-assay coefficient variation were below 15%. It had 22.3% cross-reactivity (CR%) to dobutamine and little or no CR to other compounds. The validity of RAC-Kit in 4℃ was above 180d.



Key wordsRactopamine      Artificial antigen      Monoclonal antibody      Competitive ELISA      Rapid test kit     
Received: 19 June 2008      Published: 25 January 2009
ZTFLH:  Q819  
Corresponding Authors: zi-liang wang   
Cite this article:

张海棠 ZHANG Hai-Tang zi-liang wang rui-guang deng gai-ping zhang guo-ying fan jin-qing jiang. Generation of High Affinity Monoclonal Antibody and Development of ciELISA Kit for Rapid Detection of Ractopamine. China Biotechnology, 2009, 29(01): 50-55.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2009/V29/I01/50

[1] KANG Ke-ren,YUAN Qiang,LIANG Fei-min,WU Li-xian. Synthesis of Benzfetamine Artificial Antigen[J]. China Biotechnology, 2021, 41(7): 58-65.
[2] ZHAO Yan-shu,ZHANG Jin-hua,SONG Hao. Advances in Production of Monoclonal Antibody and Antibody Fragments in Engineered Prokaryotes and Yeast[J]. China Biotechnology, 2020, 40(8): 74-83.
[3] WANG Meng,SONG Hui-ru,CHENG Yu-jie,WANG Yi,YANG Bo,HU Zheng. Accurate Detection of Streptococcus pneumoniae by Using Ribosomal Protein L7 / L12 as Molecular Marker[J]. China Biotechnology, 2020, 40(4): 34-41.
[4] JIANG Yi-fan,JIA Yu,Wang Long,WANG Zhi-ming. The Glycosylation Design and Control of Monoclonal Antibody by Cell Culture[J]. China Biotechnology, 2019, 39(8): 95-103.
[5] LIU Guo-fang,LIU Xiao-zhi,GAO Jian,WANG Zhi-ming. Effects of Host Cell Residual Proteins on the Quality and Their Quality Control of Monoclonal Antibody[J]. China Biotechnology, 2019, 39(10): 105-110.
[6] LI Rong-qing,QUAN Chun-shan,ZHANG Li-ying,LIU Jia-lu,ZHANG Xiang,SHANG Fei. Progress in the Synthesis of Artificial Antigen[J]. China Biotechnology, 2018, 38(12): 65-75.
[7] Jian-wei REN,Jun LI,Shang-ze LI. Human CT55 Protein Prokaryotic Expression and Its Production of Monoclonal Antibody[J]. China Biotechnology, 2018, 38(11): 1-8.
[8] Kai-yun MAO,Yue-lei FAN,Heng-zhe WANG,Da-ming CHEN. Market Competition Pattern of Global PD-1/PD-L1 Monoclonal Antibody[J]. China Biotechnology, 2018, 38(11): 103-115.
[9] Jing-jing SUN,Wei-wei ZHOU,Lei-ming ZHOU,Qiao-hui ZHAO,Gui-lin LI. Advance in Large-Scale Culture of Hybridoma Cells in Vitro[J]. China Biotechnology, 2018, 38(10): 82-89.
[10] WANG Yun-long, ZHAO Er-xia, LI Yu-lin. Expression, Purification and Identification of Thymidine Kinase 1 Recombinant Protein[J]. China Biotechnology, 2017, 37(9): 15-22.
[11] WU Meng-ling, ZHOU Jia-wang, DU Jun. Development and Application of A Double Monoclonal Antibody Sandwich ELISA for the Assay of Nodal[J]. China Biotechnology, 2017, 37(3): 51-57.
[12] LI Min, WU Ri-wei. The Market Overview of Monoclonal Antibodies in Both Domestic and Abroad[J]. China Biotechnology, 2017, 37(3): 106-114.
[13] REN Hua-jing, LIU Xiao-zhi, WANG Zhi-ming, GAO Jian. Progression of Central Nervous System Disease Therapeutic Antibody Drug Application[J]. China Biotechnology, 2016, 36(9): 54-58.
[14] ZHANG Yin-chuan, LIU Meng-meng, ZHANG Ya-ting, GUI Fang, ZHANG Ai-hua, BI Lan, PAN Yong-bin. Construction and Screening of Recombinant Cell Line Expressing Fully-human mAbs against Human IgE[J]. China Biotechnology, 2015, 35(3): 66-74.
[15] WANG Lan, XIA Mao, GAO Kai. The Development and Quality Control of Antibody-Drug Conjugates[J]. China Biotechnology, 2014, 34(4): 85-94.